Cardiovascular diseases in women with gestational hypertension Circulatory System
Conditions
Interventions
This is a prospective study in women in mid to late gestation. The researchers propose to examine:
1. Changes in vascular and placental markers with gestation in normal and hypertensive pregnancy.
2.
Sponsors
University of Dundee
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Case group: Women who: 1. Are aged 18 years or above 2. Are able to give written informed consent (ICF) 3. Are in mid-to-late gestation 4. Were diagnosed with gestational hypertension (systolic BP =140 mmHg or diastolic BP =90 mmHg) in their pregnancy 5. Do not have cardiac or ophthalmic disorders Control group: Pregnant women who are: 1. Aged 18 years or above 2. Able to give written informed consent (ICF) 3. Have no gestational hypertension (normal pregnancy/non-hypertension) 4. Do not have cardiac or ophthalmic disorders
Exclusion criteria
Exclusion criteria: Exclusion criteria are the same for both case and control groups: Case group: 1. Women with ophthalmic disorders 2. Women who have hypertension during pregnancy 3. Maternal age less than 18 years at delivery 4. Women who are not capable of giving informed consent (ICF) 5. Individuals participating in the clinical phase of another interventional study or have done so within the last 30 days (unless they are participating in the follow-up phase of another interventional trial/study, or who are enrolled in an observational study, will be co-enrolled where the CIs of each study agree) Control group: 1. Women with any history of gestational hypertension (systolic BP =140 mmHg or diastolic BP =90 mmHg) 2. Women with ophthalmic disorders 3. Women who had hypertension prior to pregnancy 4. Maternal age less than 18 years at delivery 5. Women who are not capable of giving informed consent (ICF) 6. Individuals participating in the clinical phase of another interventional study or have done so within the last 30 days (unless they are participating in the follow-up phase of another interventional trial/study, or who are enrolled in an observational study, will be co-enrolled where the CIs of each study agree)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Retinal vascular health measured using retinal imaging (Canon camera) (VAMPIRE: Vascular Assessment and Measurement Platform for Images of the REtina) 2. Endothelial function measured using retinal imaging and ultrasound pulse-wave Doppler 3. Cardiovascular function biomarkers measured using blood biomarker analysis (sFlt-1 & PLGF, endothelin-1) Measured at mild-late pregnancy for women with gestational hypertension and normal pregnancies | — |
Secondary
| Measure | Time frame |
|---|---|
| Long-term cardiovascular risk indicators measured using cardiovascular risk assessment tools (e.g., blood pressure, etc) at mild-late pregnancy for women with gestational hypertension and normal pregnancies | — |
Countries
Scotland, United Kingdom
Contacts
Public ContactSarah Alkhurainej
Outcome results
None listed